CEO's Leave Puts Light On Governance Dilemma

F
Fenwick

Contributor

Fenwick logo
Fenwick provides comprehensive legal services to leading technology and life sciences companies — at every stage of their lifecycle — and the investors that partner with them. For more than four decades, Fenwick has helped some of the world's most recognized companies become and remain market leaders. Visit fenwick.com to learn more.
Fenwick corporate governance practice co-chair David Bell talked to Automotive News about the complexity of public companies' decisions about how much to disclose regarding a chief executive's health in the context of sick leave...
United States Corporate/Commercial Law

Fenwick corporate governance practice co-chair David Bell talked to Automotive News about the complexity of public companies' decisions about how much to disclose regarding a chief executive's health in the context of sick leave during the COVID 19 pandemic.

Bell told Automotive News that many companies opt to say as little as possible about a CEO's health.

"It may be risky to make an incomplete disclosure. And again, when you're trying to balance somebody's privacy interests and the risk to the company, that leans people toward not making disclosure," Bell noted.

For more information, please read the alert that Bell co-authored on when a company should disclose the news that a senior leader has a serious health challenge.

The full article is available on Automotive News (subscription required).

Originally published April 21, 2020

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More